(NASDAQ: CDTX) Cidara Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 4.08%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.96%.
Cidara Therapeutics's earnings in 2025 is -$182,981,000.On average, 3 Wall Street analysts forecast CDTX's earnings for 2025 to be -$63,335,537, with the lowest CDTX earnings forecast at -$75,354,672, and the highest CDTX earnings forecast at -$51,879,292. On average, 4 Wall Street analysts forecast CDTX's earnings for 2026 to be -$101,294,318, with the lowest CDTX earnings forecast at -$128,660,644, and the highest CDTX earnings forecast at -$73,279,500.
In 2027, CDTX is forecast to generate -$93,642,122 in earnings, with the lowest earnings forecast at -$124,899,395 and the highest earnings forecast at -$80,153,506.